REGN: Valuation Model
ππ $Regeneron Pharmaceuticals(REGN)$ ππΌπππΌππππ πππΏππ
1Y TARGET: $865 --> $930
POTENTIAL UPSIDE: +43% β
"Regeneron remains my favorite large Cap biotech, Dupixent alone justify almost totally current valuation"
ASSUMPTIONS:
LTM Revenue: $14.248B
5Y Revenue CAGR: 8%
2030 Profit Margin: 35%
2030 PE Ratio: 17 --> 18
Shares outstanding: 107.2M
Shares reduction: 2%/year
VALUATION:
Q3 2030 $REGN SHARE PRICE =
14.248 * (1.08)^5 * 0.35 * 18 /
[0.1072 * (0.98^5)] = $1361
You can now choose the discount rate that you prefer, for Regeneron I want to use 10%.
ACTUAL PRICE: $650
FAIR VALUE: $845
PRICE TARGET (1Y): $930
POTENTIAL UPSIDE: +43%
EXPECTED RETURNS: 15.9%/year
DIVIDEND YIELD: 0.5%
Do you own REGN shares?
Stock chart for Regeneron Pharmaceuticals Inc NASDAQ REGN displays current price at 651.80 USD with 21.36 percent decline over past year. Y-axis ranges from 0 to 1000 USD in increments. X-axis shows time from March 2025 to September 2025 with markers for 1D 5D 1M 6M YTD 1Y. Red line indicates sharp drop from around 800 USD in early period to below 700 USD recently then slight recovery. Background includes company name and exchange details.
For whom haven't open CBA can know more from below:
π¦ Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
Find out more hereοΌ
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
